The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

Fri, 03rd Feb 2023 15:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based pharmaceutical firm - Gives update on signal finding study of MRx0518 in combination with anti-PD-1 therapy Keytruda on patients with solid tumours that have progressed on a prior immune checkpoint inhibitor. In March, the company noted four patients with renal cell carcinoma, which had experienced durable stable disease. Renal cell carcinoma is a cancer of cells in the lining of tubules in the kidney. On Thursday, 4d Pharma says one of the four patients is partially responding to the treatment with MRx0518 in combination with anti-PD-1 therapy Keytruda. "Despite recent setbacks in the microbiome field experienced by other companies and the limitations on patient recruitment as a result of the administration, we are delighted that patients continue to benefit from the trial treatment. We continue to build on the body of evidence for the future development of MRx0518 and 4D's approach to Live Biotherapeutics," says Alex Stevenson, chief scientific officer at 4D pharma.

----------

Darktrace PLC - Cambridge, England-based cybersecurity business - Chief Executive Officer Poppy Gustafsson buys 48,000 shares for GBP2.254 each, worth GBP108,192.

----------

GCP Infrastructure Investments Ltd - Jersey, UK-based investment fund focused on UK infrastructure projects - Net asset value as at December 31 rises 6.0% to 113.59 pence per share from 107.18p a year prior. Says company was exposed to diversified and partially inflation protected portfolio with of 48 investments, up from 47 a year prior, with a valuation of GBP1.1 billion, unchanged. Like a year ago, the company's portfolio has a weight-adjusted average annualised yield of 7.9%. Says that it made five investments in the quarter to December 31, totalling GBP54.6 million, up from three investments totalling GBP52.8 million a year earlier.

----------

Greatland Gold PLC - London-headquartered mining development and exploration company, focused primarily on precious and base metal mining in Western Australia and Tasmania - Identifies bismuth in Western Australia at Juri joint venture, of which it owns 49% and Newcrest Mining Ltd 51%. Bismuth is a gold-copper mineralisation pathfinder element. Intersects 4 metres at 0.4 grams of gold per tonne at Black Hills hole, and 6 metres at 0.2 grams of gold per tonne at Black Hills hole. Notes that exploration confirms merit of follow-up drilling. Greatland Gold Managing Director Shaun Day says: "We are strongly encouraged by the results of our second drilling campaign at the Juri joint venture. The importance of bismuth as a pathfinder in the Paterson region is particularly significant with geochemistry at Black Hills similar to what we have seen at Havieron."

----------

Henderson Opportunities Trust PLC - Invests in the Asia Pacific region - Net asset value per share at October 31 falls 28% to 1,173.7p from 1,626.9p a year prior. NAV total return is negative 26%, including dividends reinvested, underperforming against its benchmark, which posts a negative return of 2.8%. Declares annual 34.0p per share dividend, up 24% from 27.5p a year prior. Looking ahead, says it is able to grow "substantially" despite a wider backdrop, with Chair Wendy Colquhoun noting that "this portfolio should not be seen as a proxy for the UK economy."

----------

Jadestone Energy PLC - Asia Pacific-focused oil and gas company - Says 2022 production averages 11,487 barrels of oil equivalent per day, down 8.4% from 12,545 a year ago. Company realises average oil price of USD103.93 per barrel in 2022, jumping 40% from USD74.34 a year ago. Revenue of about USD421 million is up 24% from USD340 million in 2021. Expects lifting of 4.0 million barrels of oil, down 13% from 4.6 million in 2021. Expects lifting of gas to triple in 2022 to 1.8 million cubic feet from 600,000 in 2021. In 2022, capital expenditure was about USD87 million, below the guidance of USD90 million to USD105 million but 55% higher than USD56.0 million in 2021. Looking into 2023, CEO Paul Blakeley says: "We are engaged in several mergers & acquisitions processes at present, and I am optimistic that we will be successful in resuming our growth trajectory in 2023, while remaining very disciplined about the opportunities we pursue."

----------

Mineral & Financial Investments Ltd - Cayman Island-based investor in the natural resources sector - Notes that Redcorp Empreedimentos Mineiros Lda finds 3.9% copper equivalent at Venda Nova South Zone in south Portugal. In addition, Mineral & Financial Chief Executive Officer Jacques Vaillancourt says: "We are encouraged by the confirmation that South Zone also appears to hold copper dominated mineralization similar to what we are seeing at depth in the North Zone. Additional drilling in the future is expected to expand on these discoveries."

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Jul 2020 14:39

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

Read more
6 Jul 2020 12:38

Next part of tumour trial begins for 4D Pharma

(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.

Read more
6 Jul 2020 10:17

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

Read more
2 Jul 2020 12:14

Patient enrolment begins for 4D's Covid therapy candidate

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.

Read more
2 Jul 2020 09:16

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

Read more
26 May 2020 10:06

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

Read more
11 May 2020 10:45

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

Read more
20 Apr 2020 11:08

4D Pharma receives expedited approval for coronavirus study

(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.

Read more
20 Apr 2020 10:30

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

Read more
17 Apr 2020 13:53

4D Pharma upbeat on key findings from Blautix study

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.

Read more
17 Apr 2020 10:14

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

Read more
18 Mar 2020 18:09

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

Read more
18 Feb 2020 18:44

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

Read more
18 Feb 2020 09:26

4D Pharma raising at least ?18m via placing and subscription

(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.

Read more
18 Feb 2020 09:03

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.